Oxytrex®: An oxycodone and ultra-low-dose naltrexone formulation

Expert Opinion on Investigational Drugs

Volumn 16, Issue 8, 2007, Pages 1277-1283

  Webster, Lynn R ^a  

^a Lifetree Clinical Research and Pain Clinic   (United States)

Author keywords

Analgesia; Chronic pain; Naltrexone; Opioids; Oxycodone; Physical dependence; Tolerance; Ultra low dose antagonist

Indexed keywords

MORPHINE; NALTREXOL; NALTREXONE; NALTREXONE PLUS OXYCODONE; OPIATE; OXYCODONE; OXYMORPHONE; OXYTREX; PLACEBO; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; HUMAN; LOW BACK PAIN; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OSTEOARTHRITIS; PATIENT COMPLIANCE; PRURITUS; SIDE EFFECT; SOMNOLENCE; WITHDRAWAL SYNDROME; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG ADMINISTRATION; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NALTREXONE; OXYCODONE;

EID: 34548285495     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.8.1277     Document Type: Article

References (13)

1. CRAIN SM, SHEN KF: Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. (1990) 11(2):77-81.
2. CRUCIANI RA, LUSSIER D, MILLER-SAULTZ D, ARBUCK DM: Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J. Pain Symp. Manage (2003) 25(6):491-494.
3. WANG HY, FRIEDMAN E, OLMSTEAD MC, BURNS LH: Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in μ opioid receptor-G protein coupling and G-βγ signaling. Neuroscience (2005) 135(1):247-261.
4. CRAIN SM, SHEN KF: Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/ dependence liability. Pain (2000) 84(2-3):121-131.
5. WANG HY, BURNS LH: G-βγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J. Neurobiol. (2006) 66(12):1302-1310.
6. CHINDALORE VL, CRAVEN RA, YU KP, BUTERA PG, BURNS LH, FRIEDMANN LH: Adding ultra-low dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized controlled trial of Oxytrex. J. Pain (2005) 6(6):392-399.
7. WEBSTER LR, BUTERA PG, MORAN LY, WU N, BURNS LH, FRIEDMANN N: Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J. Pain (2006) 7(12):937-946.
8. SPIERINGS EL, BUTERA PG, WU N, MORAN LV, FRIEDMANN N: Phase III study to assess physical dependence and analgesic efficacy of Oxytrex versus oxycodone. Presented at the 25th Annual Scientific Meeting of the American Pain Society. San Antonio, Texas, USA (4-5 May 2006). Poster 814.
9. OLMSTEAD MC, BURNS LH: Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology (2005) 181(3):576-581.
10. LERI F, BURNS LH: Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol. Biochem. Bebav. (2005) 82(2):252-262.
11. AGRAWAL YP: Low dose naltrexone therapy in multiple sclerosis. Med. Hypotheses (2005) 64(4):721-724.
12. LIU B, GAO HM, WANG JY, JEOHN GH, COOPER CL, HONG JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. AY Acad. Sci. (2002) 962: 318-331.
13. BURNS LH: Ultra-low-dose opioid antagonists enhance opioid analgesia while reducing tolerance, dependence and addictive properties. In: Recent Developments in Pain Research. Capasso A (Ed.). Kerala, India: Research Signpost (2005):115-136.